Back to dashboard
MedicaidPrior AuthMedium impact

Carve Out and Preauthorization of Spinraza and Cinryze

Maryland Medicaid·MD · Neurology, Allergy & Immunology, Hematology·Provider Transmittal
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

Maryland Medicaid is implementing new carve out policies and preauthorization requirements for Spinraza (nusinersen) and Cinryze (C1 esterase inhibitor) medications. These specialty drugs will now require prior authorization before administration and may be carved out from standard pharmacy benefits.

Action Required

Action needed
Immediately: Billing team must obtain prior authorization from Maryland Medicaid before administering Spinraza or Cinryze medications. Update billing workflows to verify authorization status before treatment. Contact Maryland Medicaid for specific authorization procedures and required documentation. Claims submitted without proper preauthorization will be denied.
Carve Out and Preauthorization of Spinraza and Cinryze | Maryland Medicaid | PolicyChanges.app